clinical activity of fianlimab, an anti-lag-3 mab combined with cemiplimab in advanced melanoma
Published 3 years ago • 501 plays • Length 3:22Download video MP4
Download video MP3
Similar videos
-
8:43
fianlimab and cemiplimab in patients with advanced melanoma
-
3:26
post adjuvant pd-1 analysis of fianlimab and cemiplimab in melanoma
-
6:17
relativity-047: relatlimab, an anti-lag-3 antibody nivolumab in first-line advanced melanoma
-
2:33
combining an anti-lag-3 antibody with nivolumab in melanoma
-
2:59
lag-3 antibody combination in immunotherapy-treated melanoma
-
7:02
nivo lag-3 antibody succeeds in advanced melanoma
-
1:43
future directions in melanoma
-
0:49
what does the future hold for lag-3 as a novel target in melanoma?
-
2:49
emerging melanoma therapeutics: ido1, lag-3 & hdac inhibitors
-
33:10
immune checkpoint inhibition in myeloid malignancies
-
3:35
keynote-006: the efficacy of ipilimumab after pembrolizumab in patients with advanced melanoma
-
24:18
pembrolizumab is better than ipilimumab for advanced melanoma in phase iii trial
-
5:00
navigating treatment-related adverse effects in lag-3 combination ici therapy for metastatic mela...
-
6:30
analyzing key data from lag-3 combinations in the treatment of metastatic melanoma
-
1:30
combinations with flt3 inhibitors: the way forward for aml treatment
-
3:14
resistance mechanisms to flt3 inhibitors in aml
-
3:21
nox2: a potential immune checkpoint for inhibition in aml
-
3:24
ipilimumab side effect management in melanoma
-
2:50
gilteritinib plus azacitidine versus azacitidine monotherapy for newly diagnosed flt3-mutated aml